ETFs Holding CRIS »    CRIS Historical Stock Prices »
CRIS News Video: Mon, Nov 9, 2015, 1:29 PM — Monday Sector Leaders: Biotechnology, Drugs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Curis is a biotechnology company, focusing on the development and commercialization of drug candidates for the treatment of cancers. Co. conducts its research and development programs both internally and through strategic collaborations. Co.'s primary drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, and phosphatidylinositol-3-kinase enzymes. Additionally, Co. has initiated an open-label Phase 2 clinical trial of CUDC-907 in patients with relapsed or refractory diffuse large B-cell lymphoma. Co. is also conducting a Phase 1 trial in patients with solid tumors, and targets to enroll patients whose cancers have MYC involvement. Self directed investors in Curis Inc will be interested in keeping up with all Curis Inc news they can find, both CRIS news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on CRIS. At RediNews, we simplify this task by presenting both CRIS news releases originating from Curis Inc itself, and CRIS news from a variety of media outlets. Visitors can browse this news online and through our CRIS RSS news feed.


CRIS News — Articles, Videos, & Press Releases

Investors Land CRIS 12.0% Cheaper Than Its Secondary Stock Offering
Monday, September 18, 2017, 10:11 AM — Dividend Channel
Implied TWOK Analyst Target Price: $93
Friday, September 1, 2017, 8:38 AM — ETF Channel
Add Up The Parts: EQWS Could Be Worth $47
Tuesday, July 25, 2017, 8:45 AM — ETF Channel
We Did The Math IWO Can Go To $188
Thursday, June 22, 2017, 8:53 AM — ETF Channel
We Did The Math IWO Can Go To $188
Thursday, June 22, 2017, 8:50 AM — ETF Channel
Analysts Anticipate UBIO Will Reach $33
Thursday, May 4, 2017, 8:49 AM — ETF Channel
Commit To Buy Curis At $2.50, Earn 58.4% Annualized Using Options
Tuesday, April 18, 2017, 1:46 PM — Stock Options Channel
Analysts Anticipate 19% Gains Ahead For UBIO
Friday, March 31, 2017, 8:51 AM — ETF Channel
CRIS is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

CMN News

RediNews invites financial news content websites to integrate our XML content for web sites by integrating our RSS feeds found throughout our website wherever news and stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic content is ideal for any financial portal or web portal, from business content web sites to corporate portal intranets. Let RediNews be your content provider of free financial content for news, perfect for location on stock market chart pages by symbol, adding another element of dynamic stock market content to your financial portal. If your web page content already includes elements like SEC filings, screener pages, historical chart information, and other cobranded financial web content, then headlines from RediNews can supplement this dynamic financial content meaningfully.

CRIS News | | Copyright © 2013 - 2018, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.